Differential behaviour of epicardial adipose tissue-secretomes with high and low orosomucoid levels from patients with cardiovascular disease in H9C2 cells.
Epicardial adipose tissue releases orosomucoid (ORM), an acute phase protein with multiple modulatory and protective properties. We aimed to identify the effect of EAT-supernatants according to their ORM levels on H9C2 cells. H9C2 were cultured with EAT-secretomes or ORM protein itself on a Real-Time Cell Analyser. Secretome proteins identification was performed by LC-mass spectrometry according to their ORM levels. Two of them were validated by ELISA in EAT-supernatants from 42 patients. ORM effect on H9C2 and neonatal rat cardiomyocytes apoptosis under hypoxia with or without fatty acid treatment was determined by Annexin-V flow cytometry measurement. Caspase-3 expression levels were determined by western blot in H9C2. Our results showed a differential effect of EAT-secretomes according their ORM levels. Although additional secreted proteins can contribute to their beneficial effects, ORM reduced hypoxia-induced apoptosis through caspase-3 inhibition. Our data showed the cardioprotective role of ORM and suggest that its quantification on EAT secretomes might help us to find new secreted factors with a cardioprotective role.
Cardiology Group, Health Research Institute, University Clinical Hospital of Santiago de Compostela, Spain; Cardiovascular Area, Center for Research in Molecular Medicine and Chronic Diseases of Santiago de Compostela, University Clinical Hospital of Santiago de Compostela, Spain.
Ricardo
R
Lage
Cardiology Group, Health Research Institute, University Clinical Hospital of Santiago de Compostela, Spain; Cardiovascular Area, Center for Research in Molecular Medicine and Chronic Diseases of Santiago de Compostela, University Clinical Hospital of Santiago de Compostela, Spain.
Isabel
I
Moscoso
Cardiology Group, Health Research Institute, University Clinical Hospital of Santiago de Compostela, Spain.
Ángel
Á
Fernández-Trasancos
Cardiovascular Area, Center for Research in Molecular Medicine and Chronic Diseases of Santiago de Compostela, University Clinical Hospital of Santiago de Compostela, Spain.
María
M
Cebro
Cardiovascular Area, Center for Research in Molecular Medicine and Chronic Diseases of Santiago de Compostela, University Clinical Hospital of Santiago de Compostela, Spain.
Marinela
M
Couselo
Department of Cardiology and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.
Rubén
R
Fandiño-Vaquero
Proteomic Unit, University Clinical Hospital of Santiago de Compostela, Spain.
Susana B
SB
Bravo
Department of Heart Surgery, University Clinical Hospital of Santiago de Compostela, Spain.
Juan
J
Sierra
Cardiology Group, Health Research Institute, University Clinical Hospital of Santiago de Compostela, Spain; Cardiovascular Area, Center for Research in Molecular Medicine and Chronic Diseases of Santiago de Compostela, University Clinical Hospital of Santiago de Compostela, Spain; Department of Cardiology and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.
José Ramón
JR
González-Juanatey
Cardiology Group, Health Research Institute, University Clinical Hospital of Santiago de Compostela, Spain. Electronic address: sonia.eiras.penas@sergas.es.
Sonia
S
Eiras
D000273:Adipose Tissue / Q000378:metabolism*; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000831:Animals, Newborn; D017304:Annexin A5 / Q000276:immunology; D017209:Apoptosis; D002318:Cardiovascular Diseases / Q000378:metabolism*; D053148:Caspase 3 / Q000378:metabolism; D015687:Cell Hypoxia; D002460:Cell Line; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D032386:Myoblasts, Cardiac / Q000378:metabolism*; D009961:Orosomucoid / Q000378:metabolism*; D010496:Pericardium / Q000378:metabolism*; D051381:Rats
D017304:Annexin A5; D009961:Orosomucoid; D053148:Caspase 3
Epicardial fat; H9C2 cells; Orosomucoid; Secretome